Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
2010 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Lineage-Specific Changes in Biomarkers in Great Apes and Humans
2015 StandoutNobel
The safety of statins in clinical practice
2007
Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes
2010
Therapeutic potential of resveratrol: the in vivo evidence
2006 Standout
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
2002
Effects of the Antifungal Agents on Oxidative Drug Metabolism
2000
Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?
2009
Cytochrome P450: taming a wild type enzyme
2011 StandoutNobel
Caenorhabditis elegans pathways that surveil and defend mitochondria
2014 StandoutNatureNobel
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Cytochrome P450 reaction-phenotyping: an industrial perspective
2007
Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3
2003
The metabolic syndrome
2010 Standout
Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks
2012
Rosuvastatin for the Treatment of Hypercholesterolemia
2005
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
2014
Generation of Human Chiral Metabolites of Simvastatin and Lovastatin by Bacterial CYP102A1 Mutants
2010
HMG-CoA Reductase Inhibitors and Myotoxicity
2000
Copper‐Catalyzed CH Bond Direct Chalcogenation of Aromatic Compounds Leading to Diaryl Sulfides, Selenides, and Diselenides by Using Elemental Sulfur and Selenium as Chalcogen Sources Under Oxidative Conditions
2013
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
2005
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
1999
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
The metabolic syndrome
2005 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Safety Considerations with Fibrate Therapy
2006
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study
2011
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism
2007
Statin Safety: A Systematic Review
2006
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Excretion and ecotoxicity of pharmaceutical and personal care products in the environment
2005
Combination statin–fibrate therapy: safety aspects
2008
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
2009
Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil
2004
Pharmacokinetics and metabolism in early drug discovery
1999
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
2008 Standout
The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin
2003
Statin-Associated Myopathy with Normal Creatine Kinase Levels
2002 Standout
Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug Design
2006
Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
2004
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities
2005 Standout
Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects
2003
HMG‐CoA reductase inhibitors and P‐glycoprotein modulation
2001
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Statin-Associated Myopathy
2003
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
The role of drug metabolizing enzymes in clearance
2014
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
2004
A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment
2014 Standout
Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry
2006
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
2004
Comparative pharmacology of rosuvastatin
2003
Aristolochic acid nephropathy: A worldwide problem
2008 Standout
Multicomponent reactions for the synthesis of pyrroles
2010 Standout
Removal of cytostatic drugs from aquatic environment: A review
2013 Standout
Combination therapy in dyslipidemia: Where are we now?
2014
A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in Caenorhabditis elegans
2015 StandoutNobel
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
3d Transition Metals for C–H Activation
2018 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Cytochrome P450 2C8 Pharmacogenetics: A Review of Clinical Studies
2009
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
1990 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Prediction of Drug Absorption Using Multivariate Statistics
2000 Standout
Electro-Fenton Process and Related Electrochemical Technologies Based on Fenton’s Reaction Chemistry
2009 Standout
P-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design
2005
Cardiovascular Events as a Function of Serum Bilirubin Levels in a Large, Statin-Treated Cohort
2012
The Many Roles for Fluorine in Medicinal Chemistry
2008 Standout
Oxadiazoles in Medicinal Chemistry
2011 Standout
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Human Pharmaceuticals in the Aquatic Environment: A Challenge to Green Chemistry
2007
Mechanisms of Cancer Drug Resistance
2002 Standout
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
In vitro length-tension relations of human ventricular aneurysms
1973
Uptake of Diet Resveratrol into the Human Low-Density Lipoprotein. Identification and Quantification of Resveratrol Metabolites by Liquid Chromatography Coupled with Tandem Mass Spectrometry
2005
Approach to the Patient Who Is Intolerant of Statin Therapy
2010
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
2004
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Photodegradation of the pharmaceuticals atorvastatin, carbamazepine, levofloxacin, and sulfamethoxazole in natural waters
2005
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Synthetic Approaches and Pharmacological Activity of 1,3,4-Oxadiazoles: A Review of the Literature from 2000–2012
2012
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Pharmacogenetics of Gilbert‘s Syndrome
2008
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
2010
Bioactivation of 2,3-Diaminopyridine-Containing Bradykinin B1 Receptor Antagonists: Irreversible Binding to Liver Microsomal Proteins and Formation of Glutathione Conjugates
2005
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
2004
Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
2011
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
2004
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Bennett Ma being referenced
Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of α v β 3 - antagonists in rat: limited role of P-glycoprotein
2002
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia
2012
Cytochrome P450 3A-Dependent Metabolism of a Potent and Selective γ-Aminobutyric AcidAα2/3 Receptor Agonist in Vitro: Involvement of Cytochrome P450 3A5 Displaying Biphasic Kinetics
2007
Metabolic interactions between mibefradil and HMG‐CoA reductase inhibitors: an in vitro investigation with human liver preparations
1999
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
2002
Acyl Glucuronidation and Glucosidation of a New and Selective Endothelin ETA Receptor Antagonist in Human Liver Microsomes
2003
Novel Cytochrome P450-Mediated Ring Opening of the 1,3,4-Oxadiazole in Setileuton, a 5-Lipoxygenase Inhibitor
2011
CYTOCHROME P450 2C8 (CYP2C8)-MEDIATED HYDROXYLATION OF AN ENDOTHELIN ETA RECEPTOR ANTAGONIST IN HUMAN LIVER MICROSOMES
2004
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
2002
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6
2003
Eplerenone Decreases Inflammatory Foci in Spontaneously Hypertensive Rat Hearts With Minimal Effects on Blood Pressure
2009
SOLVENT EFFECT ON cDNA-EXPRESSED HUMAN SULFOTRANSFERASE (SULT) ACTIVITIES IN VITRO
2003
In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism.
1998
Study of infarcted myocardium in cardiac shock.
1970
Drug Interactions with Calcium Channel Blockers: Possible Involvement of Metabolite-Intermediate Complexation with CYP3A
2000
SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL
2004
beta-Oxidation of simvastatin in mouse liver preparations.
2001
In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
1997